Applied Therapeutics’ Pivotal Galactosemia Product Stalls, Confirming Analyst Concerns
Analysts’ fears have been confirmed as a US FDA demand for clinical outcomes data has forced Applied Therapeutics to delay a planned filing for its lead product candidate, AT-007, in the rare disease galactosemia based on biomarker data alone.
You may also be interested in...
A slow start to the year in health care is usually tempered by announcements that build up to investor conference season. However, early 2022’s plethora of negative announcements may continue biotech’s unloved status of 2021.
The firm’s BTK inhibitor tolebrutinib has been put on clinical hold by the US FDA following liver injuries, but advanced trials should continue as normal since most patients have passed the 60-day mark.
The Irish firm’s cannabis-derived nabiximols spray missed the primary endpoint in a late-stage multiple sclerosis spasticity trial, but it is unfazed as hopes remain for two ongoing spasticity studies.